Obesity Clinical Trial
Official title:
Nutrition, Allergy, Mucosal Immunology and Intestinal Microbiota (NAMI): Pre-, Peri- and Postnatal Programming and Origins of Disease: Early Targeting the Epidemics of Allergy and Overweight
Combined programme: Nutrition, Allergy, Mucosal immunology and Intestinal microbiota (NAMI)
was created with the objective to reverse the rising trend of chronic inflammatory diseases,
such as allergic disease and obesity, by control of the internal and external environments
of the infant. To approach this problem, the project aims to characterize
- how immunology is regulated during pregnancy and early infancy,
- how the immune interaction between mother and child is influenced by nutritional and
microbial factors, and
- how the regulation is related to disease risk.
While allergic diseases comprise the most common chronic disease in childhood, obesity is
the most prevalent nutritional disorder among children throughout the world. In Europe, an
estimated 20% of children and adolescents are overweight with one-third of these being
considered obese. Moreover, escalation of these problems is expected in the future, since
the velocity of propagation is highest in children. Although genetic factors can determine
the propensity of an individual to become allergic or obese, these unlikely explain the
recent and progressive worldwide increases in incidence. Rather, it would appear that the
environmental changes more directly shape the risk during a critical period of life when the
scene is set for the consolidation of the immune responder type. Prenatal environmental
exposures may alter gene expression via epigenetic mechanisms, heritable changes in gene
expression occurring without alterations in the DNA sequences.
Specifically current research interest is directed towards health promotion and reducing the
risk of disease evaluating the probiotic effects with specific foods and nutrients, and
assessing their interactions in optimal combination and food matrix. For this purpose a
series of interventions studies evaluate the both the optimal timing of probiotic
intervention and the optimal mode of administration.
Sections:
Prenatal
RCT 2 Randomized, parallel-design clinical trial of 3 groups. Pregnant women (n=256) from
families with at least one member having an allergic disease have been recruited from
maternal welfare clinics and randomly assigned to control group or one of the intervention
groups. Mothers in the dietary intervention groups received dietary counselling with
specific attention to the quality and quantity of fat in the diet. To promote the
achievement of current dietary recommendations, mothers have been provided with foods which
have a favourable fat composition (e.g. spreads). The subjects in the intervention groups
have been further randomized (double-blind randomization) to receive either placebo or a
probiotic preparation, 1010 cfu of both Lactobacillus rhamnosus GG and Bifidobacterium
lactis and controls received placebo in a single-blind manner. Dietary food products and
probiotic supplementation have been continued from the 1st trimester of pregnancy until the
end of exclusive breast feeding, maximum of 6 months.
Perinatal
RCT 1 Randomized double-blind, placebo-controlled study of 2 groups. Pregnant women (n=159)
have been randomized into one of the study groups 2-4 weeks before term to receive placebo
(microcrystalline cellulose) or probiotic Lactobacillus rhamnosus GG (ATCC 53103; 1010 cfu).
After delivery probiotics/ placebo were administered orally to the infants for 6 months.
General information to prevent allergy has been given in written form to all: to breast-feed
for at least 4-6 months; to begin solid foods at 4-6 months; no smoking by caretakers.
RCT 3 Randomized double-blind, placebo-controlled clinical trial of 3 groups. Pregnant women
(n=241) with a history of atopic diseases have been assigned to one of the treatment groups:
to receive for 2 months before delivery and for 2 months thereafter, when they are
breast-feeding, either placebo or Lactobacillus rhamnosus and Bifidobacterium longum or
Lactobacillus paracasei and Bifidobacterium longum.
Postnatal
RCT 4 Randomized double-blind, placebo-controlled study of 3 groups. Neonates (n=94)
fulfilling the following criteria: gestational age at birth between 32nd and 36th weeks,
weight over 1500 g and no congenital defects of gastrointestinal system or other defects
that prevent enteral nutrition, have been randomized to receive either placebo
(microcrystalline cellulose) or a probiotic preparation (Lactobacillus rhamnosus GG, ATCC
53103) or a prebiotic preparation (a mixture of Polydextrose and Galacto-oligosaccharideOS
in a 1:1 ratio). The treatment continues for 2 months.
RCT 5 Randomized double-blind, placebo-controlled clinical trial of 2 groups. 2-6 weeks old
formula- and breast-fed colic infants (n=30), who cry without medical cause for 3h/d, for
3days/week, have been randomized to receive either placebo (microcrystalline cellulose) or a
probiotic preparation (Lactobacillus rhamnosus GG, ATCC 53103) for 4 weeks. Formula-fed
infants receive extensively hydrolysed formula and mothers of breast-fed infants avoid cow's
milk in their diet.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04101669 -
EndoBarrier System Pivotal Trial(Rev E v2)
|
N/A | |
Recruiting |
NCT04243317 -
Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults
|
N/A | |
Terminated |
NCT03772886 -
Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball
|
N/A | |
Completed |
NCT03640442 -
Modified Ramped Position for Intubation of Obese Females.
|
N/A | |
Completed |
NCT04506996 -
Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2
|
N/A | |
Recruiting |
NCT06019832 -
Analysis of Stem and Non-Stem Tibial Component
|
N/A | |
Active, not recruiting |
NCT05891834 -
Study of INV-202 in Patients With Obesity and Metabolic Syndrome
|
Phase 2 | |
Active, not recruiting |
NCT05275959 -
Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI)
|
N/A | |
Recruiting |
NCT04575194 -
Study of the Cardiometabolic Effects of Obesity Pharmacotherapy
|
Phase 4 | |
Completed |
NCT04513769 -
Nutritious Eating With Soul at Rare Variety Cafe
|
N/A | |
Withdrawn |
NCT03042897 -
Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer
|
N/A | |
Completed |
NCT03644524 -
Heat Therapy and Cardiometabolic Health in Obese Women
|
N/A | |
Recruiting |
NCT05917873 -
Metabolic Effects of Four-week Lactate-ketone Ester Supplementation
|
N/A | |
Active, not recruiting |
NCT04353258 -
Research Intervention to Support Healthy Eating and Exercise
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Recruiting |
NCT03227575 -
Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control
|
N/A | |
Completed |
NCT01870947 -
Assisted Exercise in Obese Endometrial Cancer Patients
|
N/A | |
Recruiting |
NCT05972564 -
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
|
Phase 1/Phase 2 | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Recruiting |
NCT05371496 -
Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction
|
Phase 2 |